Max Hodak, a former executive at Neuralink, has embarked on an ambitious journey by founding a new brain-computer interface company called Science Corporeal. Their innovative project, named “Science Eye,” is set to transform the treatment of blindness while also paving the way for advancements in virtual and augmented reality technology.
In a recent conversation with Futurism, Hodak elaborated on the features of Science Eye, which merges gene therapy with a cutting-edge microLED display to restore vision for those affected by visual impairments. The initial trials conducted on rabbits have yielded encouraging outcomes, and human trials are anticipated to begin in about eighteen months.
Hodak foresees a future where immersive virtual realities can be accessed without invasive procedures. Science Corporeal aspires to break through the limitations of existing VR headsets, providing users with a seamless augmented and virtual reality experience through sophisticated technology.
While some may liken Science Corporeal to Neuralink, the new venture distinguishes itself with a distinct technical methodology and a commitment to steady, sustainable growth. With a substantial funding of $160 million, the startup is poised to become a formidable contender in the brain-computer interface landscape.
As it looks to the future, Science Corporeal is committed to advancing its pioneering technology for patients, extending its vision beyond mere visual aids. The company’s prudent approach and focus on practical applications set it apart in the swiftly changing domain of neurotechnology.
With Science Corporeal at the forefront of innovation, the potential to enhance human experiences through advanced technological solutions seems limitless. Keep an eye on this groundbreaking startup as it charts its course ahead.
